NeoGenomics, Inc. (NEO): Price and Financial Metrics


NeoGenomics, Inc. (NEO)

Today's Latest Price: $36.31 USD

0.20 (0.55%)

Updated Jul 9 6:55pm

Add NEO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

NEO Stock Summary

  • With a one year PEG ratio of 121,831.8, Neogenomics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.96% of US stocks.
  • NEO's current price/earnings ratio is 1,101.87, which is higher than 99.65% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NEO is currently 367.89, higher than 99.1% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Neogenomics Inc, a group of peers worth examining would be LSBK, MLAB, UCTT, SBAC, and MOBL.
  • NEO's SEC filings can be seen here. And to visit Neogenomics Inc's official web site, go to www.neogenomics.com.
NEO Daily Price Range
NEO 52-Week Price Range

NEO Stock Price Chart Technical Analysis Charts


NEO Price/Volume Stats

Current price $36.31 52-week high $36.80
Prev. close $36.11 52-week low $18.52
Day low $35.90 Volume 824,500
Day high $36.80 Avg. volume 1,040,357
50-day MA $28.65 Dividend yield N/A
200-day MA $27.18 Market Cap 3.82B

NeoGenomics, Inc. (NEO) Company Bio


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.


NEO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NEO Latest Social Stream


Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.

Hedge Funds Are Souring On NeoGenomics, Inc. (NEO)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 5, 2020

NeoGenomics Schedules its Second Quarter Earnings Release for July 28, 2020

FT. MYERS, FL / ACCESSWIRE / July 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2020 ...

Yahoo | July 1, 2020

NeoGenomics launches solid tumor liquid biopsy tests

NeoGenomics ([[NEO]] +5.3%) launches three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases.These new tests provide a peripheral blood option for detection of therapeutic targets and prognostic markers, and the three new assays have a turnaround time of seven days...

Seeking Alpha | June 29, 2020

NeoGenomics Launches Comprehensive Suite of Solid Tumor Liquid Biopsy Tests for Cancer Patients

FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy tests for advanced ...

Yahoo | June 29, 2020

Benzinga's Top Upgrades, Downgrades For June 25, 2020

Upgrades * Credit Suisse changed the rating for Allstate Corp (NYSE: ALL) from Underperform to Neutral. Allstate earned $3.54 in the first quarter, compared to $2.30 in the year-ago quarter. The stock has a 52-week-high of $125.92 and a 52-week-low of $64.13. Allstate's stock last closed at $92.96 per share. * SunTrust Robinson Humphrey upgraded the stock for Diamondback Energy Inc (NASDAQ: FANG) from Hold to Buy. For the first quarter, Diamondback Energy had an EPS of $1.45, compared to year-ago quarter EPS of $1.39. The stock has a 52-week-high of $111.84 and a 52-week-low of $14.55. Diamondback Energy's stock last closed at $41.90 per share. * Goldman Sachs changed the rating for Ameriprise Financial Inc (NYSE: AMP) from Neutral to Buy. For the first quarter, Ameriprise F...

Yahoo | June 25, 2020

Read More 'NEO' Stories Here

NEO Price Returns

1-mo 31.53%
3-mo N/A
6-mo 20.59%
1-year 58.91%
3-year 303.44%
5-year 450.15%
YTD 24.14%
2019 131.96%
2018 42.33%
2017 3.38%
2016 8.89%
2015 88.73%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8509 seconds.